Astellas Obtains FDA Approval For Lexiscan
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma obtained U.S. FDA approval for Lexiscan injection, an A2A adenosine receptor agonist approved for use as a pharmacological stress agent in radionuclide myocardial perfusion imaging studies in patients unable to undergo adequate stress exercise testing. Astellas America Inc. obtained development and marketing rights of Lexiscan in North America from CV Therapeutics. Per the agreement between the firms, CV Therapeutics will now receive milestone payment of $12 million from Astellas. (Click here for more - Japanese language